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Abstract
C-peptide is produced in equal amounts to insulin and is the best measure of endogenous insulin secretion in patients with
diabetes.Measurement of insulin secretion usingC-peptide canbe helpful in clinical practice: differences in insulin secretion
are fundamental to the different treatment requirements of Type 1 and Type 2 diabetes. This article reviews the use of
C-peptide measurement in the clinical management of patients with diabetes, including the interpretation and choice
ofC-peptide test and its use to assist diabetes classification and choice of treatment.Weprovide recommendations forwhere
C-peptide shouldbe used, choice of test and interpretation of results.With the rising incidence ofType 2diabetes in younger
patients, the discovery of monogenic diabetes and development of new therapies aimed at preserving insulin secretion, the
direct measurement of insulin secretion may be increasingly important. Advances in assays have made C-peptide
measurement both more reliable and inexpensive. In addition, recent work has demonstrated that C-peptide is more stable
in blood than previously suggested or can be reliably measured on a spot urine sample (urine C-peptide:creatinine ratio),
facilitating measurement in routine clinical practice. The key current clinical role of C-peptide is to assist classification and
management of insulin-treated patients. Utility is greatest after 3–5 years from diagnosis when persistence of substantial
insulin secretion suggests Type 2 or monogenic diabetes. Absent C-peptide at any time confirms absolute insulin
requirement and the appropriateness of Type 1 diabetes management strategies regardless of apparent aetiology.
Diabet. Med. 30, 803–817 (2013)
Introduction
C-peptide is produced in equal amounts to insulin and can
therefore be used to assess endogenous insulin secretion,
including in patients who are insulin treated. Assessment of
insulin secretion is potentially helpful in clinical practice:
differences in glycaemic treatment requirements between
Type 1 and Type 2 diabetes mainly relate to the develop-
ment of absolute insulin deficiency in the former. In addition,
changes in treatment requirement with time in Type 2
diabetes also primarily relate to progressive loss of insulin
secretion capacity. Despite this measurement of the under-
lying hormone in the clinical care of those with diabetes is
infrequent.
With the rise in prevalence of Type 2 diabetes in younger
patients, the discovery of monogenic subtypes of diabetes
requiring specific management and the development of new
therapies aimed at preserving insulin secretion the measure-
ment of insulin secretion may be increasingly relevant in
clinical practice. In addition, recent advances in assays and
collection techniques have made assessment of insulin
secretion using C-peptide less expensive, more reliable and
widely available.
This article aims to review the current evidence on the role
of the measurement of C-peptide in the management of those
with diabetes. We have not addressed the use of C-peptide
measurement in the assessment of hypoglycaemia aetiology
and the potential therapeutic uses of C-peptide, which have
been extensively reviewed elsewhere [1,2].
Methods
A literature search of PubMed (http://www.ncbi.nlm.nih.
gov/pubmed) was performed for studies published up to
August 2012. Keywords used in various combinations
include C-peptide, diabetes, Type 1 diabetes, Type 2 diabe-
tes, MODY, diagnosis, classification, treatment, treatment
outcome, insulin resistance, prognosis, glucagon test, mixed-
meal test. Articles known to the authors or cited by others
were also included.
The first radioimmunoassay for C-peptide was developed
in 1970 with clinical studies following shortly after [3]. WeCorrespondence to: Angus Jones. E-mail: angus.jones@pms.ac.uk
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have deliberately emphasized studies reporting diagnostic
performance and more recent evidence (where available) in
view of improvements in the C-peptide assay (see ‘The
C-peptide assay’ below) and changes in classification and
treatment of diabetes over time [4].
C-peptide as a measure of insulin secretion
The physiology of C-peptide makes it appropriate for
assessing insulin secretion. Insulin is produced in the
pancreatic b-cells by enzymatic cleavage of the prohormone
precursor proinsulin to produce insulin and C-peptide in
equimolar amounts. C-peptide has negligible extraction by
the liver and constant peripheral clearance. Its half-life is
longer than insulin (20–30 vs. 3–5 min) and it therefore
circulates at concentrations approximately five times higher
in the systemic circulation [5,6].
C-peptide is commonly used in preference to insulin
measurement when assessing b-cell function in clinical
practice. In patients on insulin, C-peptide measurement must
be used as exogenous insulin will be detected by insulin
assays [4]. Insulin produced by the pancreas is extensively
(approximately 50%) first-pass metabolized by the liver,
both the extent of first-pass metabolism and peripheral
clearance of insulin is variable, therefore peripheral insulin
levels may not accurately reflect portal insulin secretion [7,8].
Even in non-insulin-treated patients, peripheral C-peptide
levels more accurately reflect portal insulin secretion than
measurement of peripheral insulin [5,9–11].
C-peptide levels must be interpreted with caution in renal
failure. Approximately half of C-peptide produced is
removed by the kidneys, the majority of which is degraded
via peritubular uptake with approximately 5% of total
C-peptide produced excreted unchanged in the urine [12,13].
Therefore, blood levels of C-peptide can be falsely elevated
where there is renal impairment [14]. It has also been
reported that C-peptide may be cleared to variable extents by
dialysis [15]. Mechanisms to correct for renal function when
measuring C-peptide have been suggested, but are currently
poorly validated [16].
Although C-peptide provides a robust measure of insulin
secretion in a person without renal impairment, the impact
of a given level of insulin secretion will depend on an
individual’s insulin resistance, which can vary widely.
Patients with declining insulin secretion will develop diabetes
earlier when they are insulin resistant rather than insulin
sensitive [17]. Therefore, an obese insulin-resistant patient
may have normal or high C-peptide at the presentation even
if they have autoimmune Type 1 diabetes and will go on to
develop absolute insulin deficiency [18,19]. This example
illustrates an important difference between the use of
C-peptide and islet autoantibody testing. C-peptide gives a
measure of the patient’s current status (does the patient
produce endogenous insulin now?) and has greater utility
further from diagnosis, when rapid decline is less likely.
Autoantibodies are of prognostic value (will they continue to
produce endogenous insulin in the future?) and have greatest
utility at diagnosis [20].
The C-peptide assay
There have been recent improvements in the C-peptide assay.
Early radioimmunoassays were time-consuming (and there-
fore expensive), subject to interference and often imprecise
[4,21,22]. The advent of highly sensitive and specific non-
isotopic assays (chemiluminescence, fluorescence, etc.) uti-
lizing monoclonal antibodies has reduced assay costs (to
approximately £10 in our laboratory) and improved detec-
tion limits and reproducibility. Cross reactivity with proin-
sulin is generally < 10% with modern assays and of little
relevance in most clinical scenarios [as proinsulin circulates
in much lower concentrations than C-peptide (pmol/l vs.
nmol/l)] [4,23].
Despite these advances, some limitations remain with
current assays. A large number of commercially available
C-peptide assays are in use worldwide and have significant
variations in comparability of results and precision [24].
Optimal standardization of C-peptide measurement between
laboratories has yet to be achieved, meaning C-peptide results
produced by different methods, and in some cases by different
laboratories using the same methods, may not be comparable,
particularly at higher C-peptide concentrations [24,25]. This
means that caution is needed when interpreting C-peptide
values in relation to those derived from research studies that
may have used other methods, particularly where a patient’s
result is close to a threshold value for a clinical decision.
An additional barrier to the use of C-peptide in clinical
care is a lack of available reference ranges for specific
populations with diabetes. Ranges quoted by many labora-
tories relate to the normal population and a relevant
population-based reference may be lacking, particularly
where a non-fasting test is used. Data quoted in published
research may relate to different assays or populations and is
rarely presented as a reference range.
Units for reporting of C-peptide values
The use of very different measurement units for reporting
C-peptide values can lead to confusion in clinical care.
C-peptide is commonly reported in nmol/l, pmol/l or ng/ml.
All values in this article are reported as nmol/l. 1 nmol/
l = 1000 pmol/l = 3 ng/ml.
Measurement of C-peptide
Sample handling
Traditional strict requirements for handling of blood
C-peptide samples may not be necessary. Many laboratories
recommend immediate transport of C-peptide samples to the
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laboratory on ice, with rapid centrifugation, separation and
frozen storage if the sample cannot be immediately processed
[4,26]. This reflects concerns about stability and limits
C-peptide measurement to healthcare settings with suitably
equipped on-site laboratories or, alternatively, where imme-
diate centrifugation and freezing of samples is possible.
There is increasing evidence these sample handling
requirements are not appropriate. C-peptide in whole blood
collected in potassium ethylenediaminetetraacetic acid
(EDTA) (rather than the more commonly used serum gel)
and measured using modern immunoassay analysers is stable
at room temperature for at least 24 h; in contrast, C-peptide
in blood collected into serum gel or plain sample tubes is
stable for 6 h but shows marked degradation by 24 h [27–
29].
Measurement of C-peptide in blood
When assessing insulin production, C-peptide can be mea-
sured in a fasting or non-fasting (‘random’) sample or in a
formal stimulation test (e.g. after intravenous glucagon or a
standardized mixed-meal test). While formal stimulation
tests are most accurate and reproducible for research
purposes, a fasting or non-fasting (‘random’) sample is
usually suitable in clinical practice if the sampling conditions
(timing relative to food and associated glucose) are known.
Median and interquartile ranges of C-peptide measured
fasting, non-fasting (random) and after-glucagon stimulation
in those meeting strict criteria for Type 1 and Type 2
diabetes in a predominantly Caucasian Swedish adult pop-
ulation are shown in Fig. 1. Approximate equivalent values
of fasting and stimulated C-peptide for key clinical thresh-
olds are shown in Table 1. Where C-peptide is referred to as
‘stimulated’ or ‘post-stimulation’ in these tables and through-
out the article, we are referring to the absolute post-
stimulation C-peptide value, rather than the increment above
baseline sometimes reported, which we do not advocate for
clinical use.
Fasting C-peptide measurement is logical when assessing
insulin resistance in patients not treated with insulin (see
separate section). However, b-cell stimulation in the fasting
state may be reduced by the hypoglycaemic effect of
concomitant insulin administration [30,31]. Therefore,
where assessing b-cell function, measurement of C-peptide
after stimulation may be advantageous [32,33]. Correlations
between fasting C-peptide and post-stimulation C-peptide
are high in insulin-treated patients (r = 0.84–0.99) [34–37];
however, the use of stimulated C-peptide (including non-
fasting ‘random’ samples) does appear to offer modestly
better clinical utility [38–41].
It has been proposed that C-peptide results are corrected
for concurrent glucose measurement. While this appears to
better correlate with b-cell mass and glucose intolerance after
islet cell transplant, there are limited published data using
this approach in clinical practice, making interpretation of
this ratio difficult [16,30,42]. A pragmatic approach is to
measure concurrent glucose to exclude hypoglycaemia
(which will suppress insulin and C-peptide) with a glucose
> 8 mmol/l considered a stimulated value [31,39]. The
homeostasis model assessment (HOMA) B calculation using
fasting insulin and C-peptide is not advised for use in clinical
practice and is not valid in those on insulin therapy [42–44].
Non-fasting ‘random’ C-peptide is likely to be the most
easily performed blood test of insulin secretion in the clinical
setting. A large study of C-peptide in the classification of
adult diabetes suggested non-fasting random C-peptide with
a concurrent glucose over 8 mmol/l was superior to both
fasting and glucagon-stimulated C-peptide measurement in
correctly classifying clinically well-defined Type 1 and
Type 2 diabetes [39]. Random non-fasting C-peptide appears
superior to fasting C-peptide in classifying diabetes based on
autoantibody status [38]. However, the utility of random C-
peptide measurement has otherwise been little examined.
Despite this, it is likely that in many clinical situations a
random (and therefore presumably imprecise) measure of
insulin secretion may suffice. The spread of C-peptide levels
is wide and a high or very low level will exclude or confirm
severe insulin deficiency; a fasted or stimulated test could
then be conducted should the result be indeterminate.
Where formal post-stimulation C-peptide measurement is
desired, there is a wide range of published stimulation
methods that have been used. The best evidenced are the
glucagon test (serum C-peptide measured 6 min after intra-
venous glucagon 1 mg intravenously given in the fasting
state) and mixed-meal tolerance test [serum C-peptide
measured 90–120 min (or area under curve over 120 min)
after a liquid mixed meal (commonly SustacalTM; Mead
Johnson & Company, Evansville, IN, USA or BoostTM; Nestle´
Health Science, Lutry, Switzerland 6 ml/kg up to a maxi-
mum 360 ml) given in the fasting state] [34,45–49]. A
definitive comparison in early Type 1 diabetes shows that
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FIGURE 1 Boxplot of random non-fasting (with glucose > 8 mmol/l),
fasting and glucagon-stimulated C-peptide in well-defined (on clinical
features) Type 1 (n = 371) and Type 2 (n = 732) diabetes. Redrawn
with permission from Berger et al. (2000) [39]. Horizontal line
represents median, box interquartile range, ‘whiskers’ represent 10–
90% of values.
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C-peptide at 90 min in the mixed-meal tolerance test is more
reproducible than post-glucagon C-peptide measurement and
better tolerated [34]. The liquid mixed meals used in major
research trials (e.g. SustacalTM and BoostTM) are not easily
obtainable in many European countries, including the UK,
although it is likely that preparations with broadly similar
nutritional content will be interchangeable.
Measurement of C-peptide in urine
Urine C-peptide measurement is a potentially attractive non-
invasive measure of b-cell function. C-peptide is excreted in
the urine through glomerular filtration and uptake from
peritubular capillaries. The total quantity of C-peptide
excreted in the urine per day represents approximately 5%
of pancreatic secretion, compared with only 0.1% of secreted
insulin [50]. The concentration in urine is typically 10–20
times higher than in plasma and the absence of proteases
found in blood mean that C-peptide is more stable—at room
temperature a sample collected in boric acid (standard
midstream urine container) is stable for at least 72 h and a
sample without preservative 24 h [51].
While many studies have demonstrated strong correlation
between total 24-h urine C-peptide and serum C-peptide
[33,52–55], others have shown only modest correlation
[35,56–58]. There appears to be inter/intra-individual
variation in the fraction of secreted C-peptide appearing
in the urine [58] and urinary C-peptide clearance appears
to be higher in diabetes, likely through hyperglycaemia
increasing the glomerular filtration rate [56,59–61]. These
concerns and the practical difficulties of 24-h urine collec-
tion have limited the use of 24-h urine C-peptide in clinical
practice.
Correcting for creatinine adjusts urine C-peptide concen-
tration for variation in urine concentration and enables the
use of ‘spot’ urine samples in place of 24-h urine collection.
Recent work by the Exeter group has shown 2-h urine
C-peptide:creatinine ratio is highly correlated with serum
C-peptide measurements in the mixed-meal tolerance test in
insulin-treated diabetes (r = 0.82 [62] to r = 0.97 [63]) and
with meal stimulated C-peptide in non-insulin-treated
diabetes [64].
Home samples collected in boric acid after a patients
largest meal of the day and returned for analysis by post
remain well correlated with mixed-meal test serum C-peptide
(r = 0.83, combined data from reference [63] and [62],
insulin-treated diabetes) and are a sensitive and specific test
for the presence of significant endogenous insulin secretion
and differentiating long-standing Type 1 diabetes from other
diabetes subtypes (Fig. 2) [62,63,65]. Values of urine
Table 1 Suggested C-peptide thresholds to support clinical decisions in patients with insulin-treated diabetes
Clinical role
Stimulated (non-fasting
‘random’/post-glucagon/
mixed-meal test) (nmol/l) Fasting (nmol/l)
Post-meal home meal
urine C-peptide:creatinine
ratio (nmol/mmol)
Absolute insulin deficiency/absolute insulin requirement [76] < 0.2 < 0.08 < 0.2
Likely Type 1 diabetes/inability to achieve glycaemic control
with non-insulin therapies [39,40,95]
< 0.6 < 0.25 < 0.6
Suggests Type 2 or monogenic (MODY) diabetes in a patient
with presumed Type 1 diabetes > 3–5 years post-
diagnosis [65,71]
> 0.2 > 0.08 > 0.2
Consider MODY/Type 2 diabetes in young onset diabetes at
diagnosis [67]
> 1 > 0.4 > 1.1
Equivalent thresholds for stimulated and fasting C-peptide and urine C-peptide:creatinine ratio have been calculated from a data set of 120
research participants with insulin-treated diabetes and 90-min post-mixed-meal and fasting C-peptide and home urine C-peptide:creatinine
ratio measurements using linear regression with zero origin [37,62,63]. These thresholds are approximate; values close to thresholds should
be treated with great caution and may not assist clinical decision making.
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FIGURE 2 Boxplot using post-home meal urine C-peptide:creatinine
ratio to discriminate Type 1 diabetes of over 5 years’ duration (n = 70)
from Type 2 diabetes (n = 64) and HNF1A/4A MODY (n = 81).
Adapted with permission from Besser et al. (2011) [65] (redrawn from
original data). Cut-off of 0.2 nmol/mmol 96% sensitive and 98%
specific in differentiating Type 1 diabetes from Type 2 diabetes or
MODY (area under the receiver operating characteristic curve 0.99).
Horizontal line represents median, box interquartile range, ‘whiskers’
represent the spread of remaining values. (o) outliers over 1.5 times the
interquatile range, (*) outliers over 3 times the interquartile range.
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C-peptide:creatinine ratio for key clinical thresholds are
shown in Table 1, alongside equivalent values of fasting and
stimulated blood C-peptide. Urine C-peptide:creatinine ratio
levels are 1.5-fold higher in women than men, as a result of
higher creatinine levels in men; however, we do not currently
advocate correction for clinical use [66].
Summary
In summary, a range of tests are available to clinicians to
assess insulin secretion. It is likely that, in the majority of
clinical scenarios, a less intensive test such as non-fasting
‘random’ blood C-peptide, fasting blood C-peptide or post-
meal urine C-peptide:creatinine ratio will be sufficient. If
maximum accuracy is required, a mixed-meal tolerance test
is best tolerated and has highest reproducibility, but is
more time-consuming than a one-off sample or glucagon
test.
Clinical utility of C-peptide measurement
Classification of diabetes
Differentiating Type 1 and Type 2 diabetes
An important clinical role of C-peptide is differentiating
between Type 1 and Type 2 diabetes. Utility is greatest in
long-standing diabetes as there may be a substantial overlap
of C-peptide levels between Type 1 and Type 2 diabetes at
the time of diagnosis.
Key studies reporting diagnostic performance in differen-
tiation of Type 1 and Type 2 diabetes are summarized in
Table 2. A major limitation in interpreting these studies is
the lack of a gold standard for the diagnosis of Type 1 or
Type 2 diabetes and, in many cases, the potential incorpo-
ration of the C-peptide result into a ‘clinical’ classification,
which may lead to positive bias. Where diabetes is classified
purely on the basis of the presence or absence of autoanti-
bodies, C-peptide remains a relatively good predictor with
better performance than either age of diagnosis or BMI
[18,38].
An additional limitation is that the development of
absolute insulin deficiency is a key feature of Type 1 diabetes
and more relevant marker of subtype (and treatment
requirements) than clinical characteristics such as age of
diagnosis and BMI, both of which increasingly overlap
between Type 1 and Type 2 diabetes as obesity rates
increase. For example, if age and BMI suggest Type 2
diabetes, but the patient has absolute insulin deficiency,
following guidelines for Type 1 diabetes therapy (such as
multiple daily injections or continuous subcutaneous insulin
infusion with carbohydrate counting) are likely to be
appropriate regardless of the apparent aetiology—see below
‘Detecting absolute insulin deficiency’.
The variation in optimal cut-offs and predictive value
between studies may reflect population differences (particu-
larly time from diagnosis of diabetes and prevalence of
Type 1/Type 2 diabetes, predictive value will depend on
pretest probability) and variations in both the stimulation
test and C-peptide assays used. There is substantial overlap
between C-peptide levels in Type 1 and Type 2 diabetes
close to diagnosis and this will be greatest in obese or older
patients in whom the clinical differentiation of Type 1 and
Type 2 diabetes is most difficult [18,19,67]. In Type 1
diabetes, insulin/C-peptide levels rapidly fall, therefore the
utility of C-peptide testing increases from 3 to 5 years post-
diagnosis, where the vast majority of patients with Type 1
diabetes will have low C-peptide levels (Figs 2 and 3)
[23,65].
C-peptide levels taken within the first few years of
diagnosis may be useful in confirming Type 1 diabetes if
results are low (e.g. non-fasting blood C-peptide < 0.2 nmol/
l with hyperglycaemia confirms severe insulin deficiency,
< 0.6 nmol/l Type 1 diabetes likely). However, higher results
should be interpreted with caution (particularly in the obese
or those with features of insulin resistance—see ‘C-peptide as
a measure of insulin secretion’) and may simply reflect
continued insulin secretion seen in the early Type 1 diabetes
‘honeymoon period’. In this situation, repeated measures
may be helpful.
Identifying patients with maturity-onset diabetes of the
young (MODY)
Persistence of C-peptide is an important clinical feature of
MODY. It is particularly important to identify these patients
as they are commonly misdiagnosed as Type 1 diabetes and
treated with insulin. More than 60% of MODY is caused by
mutations in the genes HNF1A and HNF4A; these patients
are very sensitive to sulphonylurea treatment and are
commonly able to stop insulin treatment with improved
glycaemic control [68]. Other patients with glucokinase
mutations do not require glucose-lowering treatment [69]. In
contrast to Type 1 diabetes, substantial insulin secretion
persists in these forms of diabetes outside of the honeymoon
period and the persistence of C-peptide in a patient thought
to have Type 1 diabetes may be suggestive of MODY [70].
A home post-meal urine C-peptide:creatinine ratio
 0.2 nmol/mmol > 5 years post-diagnosis has 97% sensi-
tivity and 96% specificity for differentiating HNF1A/4A
MODY from Type 1 diabetes (Fig. 2) [65]. A random blood
C-peptide of  0.2 nmol/l in those with diabetes diagnosed
under 30 years of age and > 3 years’ duration has been
suggested as a criteria for consideration of MODY testing
[71]. C-peptide testing is unlikely to be useful in differenti-
ating MODY from Type 2 diabetes [65].
There are limited data available on the utility of C-peptide
testing in identifying other forms of monogenic diabetes.
Patients with mitochondrial diabetes may develop severe
insulin deficiency [72,73] and those with monogenic neonatal
diabetes commonly have absolute insulin deficiency in the
absence of sulphonylurea therapy [74]. Patients with
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Table 2 Summary of studies reporting diagnostic performance of C-peptide in differentiating Type 1 and Type 2 diabetes since 1990
Reference
Number, population and study
design C-peptide test*
C-peptide threshold and
predictive value of values below
or above threshold for diabetes
subtype or islet autoantibody
status Notes
At diagnosis of diabetes
Ludvigsson, 2012
[67]
2734 children newly diagnosed
with diabetes (Type 1 95%,
Type 2 or MODY 3%).
C-peptide alone compared with
final diagnosis incorporating
clinical features and knowledge
of autoantibody status,
C-peptide, human leukocyte
antigen (HLA) status and (in
some cases) MODY genetics
Non-fasting
‘random’
< 0.2 nmol/l > 99.8% predictive
value Type 1 diabetes
 1.0 nmol/l 46% predictive
value Type 2 diabetes or
MODY
C-peptide at diagnosis
a much stronger
predictor of Type 2
diabetes or MODY
than age or glycaemia
Thunander, 2012
[18]
1178 adults diagnosed over
20 years (mean age 66).
C-peptide at diagnosis
compared with presence or
absence of islet autoantibodies
(GAD or ICA, 4.9% antibody
positive)
Fasting < 0.6 nmol/l 30.1% predictive
value autoantibodies,
> 0.6 nmol/l 97.4% predictive
value absence of autoantibodies
C-peptide superior to
age and BMI in
discriminating
autoimmune and
non-autoimmune
diabetes
Katz, 2007 [129] 175 children with new-onset
diabetes. Type 2 diabetes (15%)
if obese, relative with Type 2
diabetes, ability to wean from
insulin, GAD antibody negative
Fasting < 0.28 nmol/l 98% predictive
value Type 1 diabetes
> 0.28 nmol/l 48% predictive
value Type 2 diabetes
Torn, 2001 [38] 486 newly diagnosed aged
15–34 years, C-peptide
measured in either fasting
or non-fasting ‘random’ and
compared with presence of islet
autoantibodies (ICA, GAD,
IA-2A, 74% antibody positive)
Fasting and non-
fasting ‘random’
Fasting < 0.3 nmol/l 85%
predictive value autoantibodies
Non-fasting < 0.3 nmol/l 94%
predictive value autoantibodies
Fasting > 1.0 nmol/l 75%
predictive value absense of
autoantibodies
Non-fasting > 1.0 nmol/l 83%
predictive value absense of
autoantibodies
Long-standing diabetes
Besser, 2011† [65] Urine C-peptide:creatinine ratio
measured post-home meal in 70
patients with Type 1 diabetes
(diagnosis age < 30 years,
insulin from diagnosis) and 69
patients with Type 2 diabetes
(diagnosis  30 years, no
insulin in first post-diagnosis
year)
Urine C-peptide:
creatinine ratio
< 0.2 nmol/mol 98.5%
predictive value Type 1 diabetes
> 0.2 nmol/l 95.3% predictive
value Type 2 diabetes
Long duration diabetes
(Type 1 diabetes median
34 years) may account
for high performance of
the low threshold in
predicting Type 2
diabetes
Berger, 2000 [39] Retrospective analysis of 1093
patients with well-defined
diabetes type (34% Type 1)
who had had C-peptide
measured in clinical care
(duration at C-peptide testing
not reported). Type 2 diabetes:
clinicians diagnosis and no
insulin for 3 years. Type 1
diabetes: clinicians diagnosis
and continuous insulin for
> 3 years from diagnosis
Fasting
Non-fasting
C-peptide with
glucose
> 8 mmol/l
Glucagon
stimulated
Fasting < 0.42 nmol/l 81.0%
predictive value Type 1 diabetes
Fasting > 0.42 nmol/l 91.3%
predictive value Type 2 diabetes
Non-fasting < 0.5 nmol/l 91.5%
predictive value Type 1 diabetes
Non-fasting > 0.5 nmol/l 95.3%
predictive value Type 2 diabetes
Glucagon-stimulated
< 0.6 nmol/l 93.9% predictive
value Type 1 diabetes
Glucagon-stimulated
> 0.6 nmol/l 77.1%
C-peptide may have
influenced diagnosis.
Included patients whose
C-peptide was measured
at or close to diagnosis
Service, 1997 [130] 346 patients with diabetes
(mostly long-standing) classified
as insulin-dependent diabetes
(24%) and non-insulin-
dependent diabetes (76%) by
clinical algorithm. Clinical
Fasting and
increment in
mixed-meal
tolerance test
Fasting C-peptide < 0.17 nmol
and mixed-meal tolerance test
increment < 0.07 predictive
value Type 1 diabetes 77%.
All other C-peptide responses
Follow-up for up to
8 years showed C-
peptide classification
remained stable
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monogenic forms of diabetes associated with severe insulin
resistance are likely to have raised C-peptide.
Summary
In summary, where there is uncertainty as to diabetes
subtype, C-peptide measurement may aid diagnosis and
therefore appropriate management. This is particularly
relevant in long-standing (> 5 years) insulin-treated diabetes
where retained substantial C-peptide secretion may be
strongly indicative that Type 1 diabetes is unlikely and
therefore Type 2 diabetes or MODY should be considered.
Detecting absolute insulin deficiency
Regardless of the aetiology/classification of a person’s
diabetes, the awareness that a person has absolute insulin
deficiency (commonly defined as < 0.2 nmol/l after a mixed-
meal test or < 0.08 nmol/l fasting [37,75,76]) is important to
clinical management. A person with absolute insulin defi-
ciency will have an absolute requirement for insulin to
prevent ketoacidosis and greater glycaemic instability, hyp-
oglycaemia risk and microvascular complications [75–77]. It
is logical that (regardless of whether their diabetes is
autoimmune in origin) these patients may particularly benefit
from ‘Type 1’ type treatments such as basal bolus insulin,
carbohydrate counting or insulin pumps, should be managed
as Type 1 diabetes during illness or surgery and will have
reduced response to therapies acting through stimulation of
endogenous insulin secretion such as sulphonylureas or
incretin-based therapies.
Treatment response
Treatment change in insulin-treated patients
C-peptide may help identify insulin-treated patients with
sufficient b-cell function to safely replace insulin with other
hypoglycaemia therapies. Early work established that stim-
ulated C-peptide of approximately 0.3–0.8 nmol/l could
differentiate insulin-requiring from non-insulin-requiring
diabetes, using definitions of acceptable control very different
from today, often without oral hypoglycaemic medications
[77–83]. Using a lower cut-off will give greater specificity for
insulin requirement, all patients with a stimulated C-peptide
< 0.2 nmol/l are likely to have an absolute requirement for
insulin. Studies since 1990 formally assessing insulin with-
drawal (and reporting diagnostic performance) are summa-
rized in Table 3. Cut-offs in these and earlier studies
(C-peptide approximately 0.6 nmol/l stimulated and
0.3 nmol/l fasting) are unsurprisingly similar to those
distinguishing Type 1 and Type 2 diabetes. It should be
noted these studies have a number of limitations, including
that they are generally of short duration and often use
definitions of acceptable glycaemia that are far less stringent
than those in use today. Few recent studies have included a
group with low C-peptide, instead excluding these patients
based on data from earlier research. Participants had a
Table 2 (Continued)
Reference
Number, population and study
design C-peptide test*
C-peptide threshold and
predictive value of values below
or above threshold for diabetes
subtype or islet autoantibody
status Notes
classification compared with
classification by C-peptide—
fasting < 0.17 nmol/l and
increment < 0.07 indicating
insulin-dependent diabetes, all
other responses defined as
Type 2 diabetes
predictive value Type 2 diabetes
93%
Prior, 1993 [41] 373 (Type 2 diabetes 114) adults
with known retinopathy
meeting study definitions of
Type 1 diabetes (n = 259,
diagnosis < 30 years, insulin
within 1 year, weight < 120%
desirable) or Type 2 diabetes
(n = 114, diagnosis > 30 years
and not on insulin or diagnosis
> 40 years and weight 120%
desirable)
Fasting and
90 min in
mixed-meal
tolerance test
Mixed-meal tolerance test
C-peptide < 0.08 nmol/
l = 100% predictive value
Type 1 diabetes. Mixed-meal
tolerance test C-peptide
> 0.08 nmol/l 91% predictive
value Type 2 diabetes.
Fasting C-peptide < or
> 0.08 nmol/l 97.4% agreement
with mixed-meal tolerance test
classification
Long duration of diabetes
(retinopathy required for
inclusion) may account
for the low threshold
chosen
Where not reported, predictive values have been calculated from published data.
All studies have predominantly Caucasian populations.
*Blood unless urine C-peptide:creatinine ratio stated.
†Type 1 diabetes vs. Type 2 diabetes diagnostic performance not reported—calculated from original study data.
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clinical diagnosis of Type 2 diabetes and were usually insulin
treated from diagnosis or had previously been treated with
only a single oral therapy.
The clinical role of C-peptide testing in this context is
likely mainly to exclude absolute insulin deficiency prior to
attempted insulin withdrawal in patients insulin treated from
diagnosis and thought unlikely to have Type 1 diabetes or
who have had long-standing insulin treatment for presumed
Type 2 diabetes.
There may be an additional role to exclude severe insulin
deficiency prior to addition of oral or glucagon-like peptide 1
(GLP-1) agonist therapy to insulin, particularly where there
is doubt about the underlying diabetes subtype. Neither
sulphonylureas nor incretin-based therapies are currently
recommended for Type 1 diabetes and treatments acting
wholly or partly through enhancing b-cell insulin secretion
would appear likely to have less response in those who do
not secrete endogenous insulin. However, direct evidence is
limited. Fasting C-peptide does not appear to predict the
effects of sulphonylurea withdrawal within those with
Type 2 diabetes who have progressed through oral therapy
to requiring insulin, this may reflect a low prevalence of
absolute insulin deficiency in this population [84–86]. A high
predictive utility of blood C-peptide for liraglutide response
in insulin-treated patients was reported in one small study
[87]; however, another has found only a small difference in
C-peptide in those able and unable to replace insulin with
exenatide [88].
There may be a potential future role of C-peptide testing in
assisting choice of insulin regimen. Many insulin-treated
patients with Type 2 diabetes achieve good glycaemic
control with intermediate or long-acting insulin alone, but
fast-acting mealtime insulin may be required as diabetes
progresses. C-peptide is inversely associated with glycaemic
variability and post-meal glucose rise in both Type 1 and
Type 2 diabetes [89–92] and is inversely associated with
response to prandial insulin in experimental conditions in a
mixed population with diabetes [93].
Insulin dependence in ketosis-prone diabetes
C-peptide measurement may help to detect adult patients
presenting with diabetic ketoacidosis who do not have
classical Type 1 diabetes and may not require long-term
insulin treatment. Patients with negative islet autoantibodies
and preserved C-peptide (fasting > 0.33 nmol/l or glucagon
response > 0.5 nmol/l) on resolution of ketoacidosis are
likely to retain endogenous b-cell function at 1 year and in
many cases achieve glycaemic control without insulin
(approximately 50% in a predominantly non-Caucasian
population [94]), in contrast to those with low initial
C-peptide levels [95,96].
Treatment change in non-insulin-treated patients
There is limited evidence to support the use of C-peptide to
predict treatment response in non-insulin-treated patients.
In a population with newly diagnosed Type 1 and Type 2
diabetes, very low C-peptide appears to be predictive for
insulin requirement. In 244 consecutively recruited patients,
low fasting C-peptide had similar predictive values for
subsequent insulin treatment to positive islet cell antibodies
(ICA): 80% of those with fasting C-peptide < 0.25 nmol/l
required insulin over a median 31 months’ follow-up [97].
In Type 2 diabetes a double-blind trial of metformin and
glibenclamide has demonstrated that achieving good glycae-
mic control with these agents in those with marked hyper-
glycaemia can be predicted by a combination of baseline
glycaemia and stimulated C-peptide levels [98]. Logistic
regression suggested the probability of a patient with a
fasting glucose of 16 mmol/l achieving glycaemic control
would vary from 15 to 85% in those with low and high
C-peptide. Retrospective observational studies [99,100]
using postprandial C-peptide:glucose ratio to predict future
insulin treatment in Type 2 diabetes are consistent with this;
however, reported test performance appears similar to that of
BMI and fasting glucose [99], and clinicians knowledge of C-
peptide status may have led to positive bias.
The large overlap between C-peptide levels in patients with
Type 2 diabetes who do and do not require insulin for
glycaemic control goes against the use of C-peptide in this
(a)
(b)
FIGURE 3 Two-hour mixed-meal test C-peptide values in relation to
diabetes duration at entry screening for the Diabetes Control and
Complications Trial in (a) adults aged > 18 years and (b) adolescents
aged < 18 years. Reproduced with permission from Palmer et al.
(2004) [23].
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context [101]. Inexpensive and effective oral hypoglycaemic
therapies are available and a trial of treatment in most cases
will be the most effective way of determining response. It is
also not clear that those with low C-peptide would have
benefited from earlier insulin therapy: low C-peptide may be
associated with poor control regardless of therapy [102,103],
although it has been reported that those with Type 2 diabetes
and fasting C-peptide < 0.2 nmol/l have better control on
insulin rather than oral treatment [104].
Evidence for a clinical role of C-peptide in predicting
response to specific hypoglycaemic agents is weak. There is
evidence that more insulin-resistant patients with higher C-
peptide values have increased response to thiazolidinediones
[105–108]. This does not appear to be the case for metfor-
min, sulphonylureas and dipeptidyl peptidase-4 (DPP-4)
inhibitors [84,105,109–111].
In summary, there is currently insufficient evidence for
more than a very limited role of C-peptide in this context.
There may be a role for assessment of C-peptide in assisting
the decision between oral and insulin therapy in those
presenting with marked hyperglycaemia, and in providing
supporting evidence for prescribing pioglitazone in a patient
suspected to have marked insulin resistance.
Glycaemic response to bariatric surgery in Type 2 diabetes
Preoperative C-peptide assessment has been shown to be
associated with remission of Type 2 diabetes after bariatric
surgery in an Asian population [112]. Remission rates were
55% in patients with preoperative fasting C-peptide
< 1 nmol/l vs. 90% in those with fasting C-peptide
> 2 nmol/l. These differences were less pronounced in the
subgroup undergoing bypass (rather than restrictive) surgery.
Summary
The current clinical role of C-peptide in predicting treatment
response is principally to exclude severe endogenous insulin
deficiency in insulin-treated patients when considering insu-
lin withdrawal or when considering the addition of therapies
dependant on endogenous insulin for their action. There may
be a limited role at the diagnosis of Type 2 (or undetermined
subtype) diabetes with marked hyperglycaemia where
C-peptide testing may support a clinical decision on initial
insulin therapy.
Determining prognosis
In Type 1 diabetes even very modest residual b-cell function
as measured by C-peptide is associated with improved
glycaemic control, less hypoglycaemia and substantial reduc-
tions in microvascular complications [76,113,114]. In the
Diabetes Control and Complications Trial study, partici-
pants with post-mixed-meal tolerance test C-peptide levels of
> 0.2 nmol/l had a 10 mmol/mol (0.9%) lower HbA1c at
baseline screening and markedly less incidence of retinopa-
thy, nephropathy and hypoglycaemia [76]. In Type 2 diabe-
tes, high C-peptide levels may be associated with features of
the metabolic syndrome and increased macrovascular com-
plications [115–117]. The relationship between C-peptide
and microvascular complications in Type 2 diabetes is
unclear, with an association found by some authors
[115,117–120], but not others [116,121,122].
Partial remission phase/honeymoon period in Type 1
diabetes
The preservation of insulin secretion often seen for an initial
period after diagnosis of Type 1 diabetes is associated with
reduced hypoglycaemia and glycaemic variability, improved
HbA1c and lower insulin requirements [92,123]. There may
be a role for using C-peptide to monitor insulin secretion
during this period in some circumstances; for example, to
help explain whether a deterioration in glycaemic control
relates to a decline in insulin secretion or to unrelated patient
factors (such as medication adherence). A future clinical role
of C-peptide testing would in pre-screening and monitoring
of response for interventions to preserve endogenous insulin
secretion should these come into clinical practice [23,124].
Islet transplantation
C-peptide can be used to assist patient selection for islet cell
transplantation and post-transplant monitoring [125]. C-
peptide < 0.1 nmol/l (fasting and/or mixed-meal tolerance
test) has been used as a criterion for islet cell transplantation
and to define complete graft failure [126].
Insulin resistance
Although fasting C-peptide can be used to derive an estimate
of insulin resistance using HOMA modelling [44], and high
uncorrected fasting C-peptide in the presence of hyperglyca-
emia may be suggestive of insulin resistance, methods based
on direct insulin measurement (rather than C-peptide) are
generally used for research purposes [127] and evidence for
use in this clinical context is limited [128].
Recommendations
We recommend C-peptide measurement in diabetes clinical
practice predominantly in insulin-treated patients where
there is uncertainty about the underlying diagnosis or
consideration of a therapy requiring residual b-cell function
for its mechanism of action. In this increasingly common
clinical context, C-peptide may assist appropriate treatment
and classification.
Numerous stimulation methods have been proposed in the
literature. In most clinical practice a fasting blood C-peptide,
non-fasting blood C-peptide in the presence of a glucose
> 8 mmol/l or post-home meal urinary C-peptide:creatinine
ratio are appropriate. Values close to clinical thresholds
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could be repeated or a more rigorous stimulated test (mixed-
meal or glucagon tests) performed.
In a person with insulin-treated diabetes, a stimulated
blood C-peptide of < 0.6 nmol/l (fasting < 0.25 nmol/l and
or post-meal urinary C-peptide:creatinine ratio < 0.6 nmol/
mmol) are suggestive of marked insulin deficiency and
Type 1 diabetes. Values over this are consistent with short-
term insulin independence in an individual who has not
previously ‘failed’ non-insulin therapy, but may occur in the
Type 1 diabetes honeymoon period. Persistence of C-peptide
above these levels after 3–5 years from diagnosis is sugges-
tive of Type 2 or monogenic diabetes.
A stimulated blood C-peptide < 0.2 nmol/l (fasting
< 0.08 nmol/l and or post-meal urinary C-peptide:creatinine
ratio < 0.2 nmol/mmol) confirms absolute insulin deficiency
and absolute insulin requirement.
Variations in C-peptide assays, stimulation methods and
insulin resistance mean results close to these suggested
thresholds should be treated with particular caution.
Conclusion
In conclusion, C-peptide measurement is an inexpensive,
widely available test that may assist the clinical management
of diabetes, particularly in insulin-treated patients where
there is uncertainty about diabetes subtype.
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